Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Ratio (2016 - 2025)

Enanta Pharmaceuticals' Equity Ratio history spans 14 years, with the latest figure at 0.38 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 19.79% year-over-year to 0.38; the TTM value through Dec 2025 reached 0.38, up 19.79%, while the annual FY2025 figure was 0.23, 32.59% down from the prior year.
  • Equity Ratio reached 0.38 in Q4 2025 per ENTA's latest filing, up from 0.23 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2021 to a low of 0.23 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.6, with a median of 0.47 recorded in 2023.
  • Peak YoY movement for Equity Ratio: crashed 51.32% in 2024, then increased 19.79% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.87 in 2021, then fell by 0.78% to 0.87 in 2022, then plummeted by 48.27% to 0.45 in 2023, then fell by 28.38% to 0.32 in 2024, then grew by 19.79% to 0.38 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Equity Ratio are 0.38 (Q4 2025), 0.23 (Q3 2025), and 0.26 (Q2 2025).